Sicca Syndrome (Sjogren) (Immunology) - Drugs in Development, 2021

November 2021 | 274 pages | ID: SD649393B9CCEN
Global Markets Direct

Abstracts

Sicca Syndrome (Sjogren) (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome - Drugs In Development, 2021, provides an overview of the Sicca Syndrome (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 8, 1, 1, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Sicca Syndrome (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Immunology).
• The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sicca Syndrome (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sicca Syndrome (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Sicca Syndrome - Overview
Sicca Syndrome - Therapeutics Development
Sicca Syndrome - Therapeutics Assessment
Sicca Syndrome - Companies Involved in Therapeutics Development
Sicca Syndrome - Drug Profiles
Sicca Syndrome - Dormant Projects
Sicca Syndrome - Discontinued Products
Sicca Syndrome - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Sicca Syndrome (Sjogren), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Sicca Syndrome (Sjogren) - Pipeline by AbbVie Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Aldeyra Therapeutics Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Alpine Immune Sciences Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Co, 2021
Sicca Syndrome (Sjogren) - Pipeline by CellAxia Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Cytodyn Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Co, 2021
Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, 2021
Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Hanlim Pharm Co Ltd, 2021
Sicca Syndrome (Sjogren) - Pipeline by Horizon Therapeutics Plc, 2021
Sicca Syndrome (Sjogren) - Pipeline by I-Mab, 2021
Sicca Syndrome (Sjogren) - Pipeline by Ibex Biosciences LLC, 2021
Sicca Syndrome (Sjogren) - Pipeline by Rise Therapeutics LLC, 2021
Sicca Syndrome (Sjogren) - Pipeline by Rophibio Inc, 2021
Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharm Co Ltd, 2021
Sicca Syndrome (Sjogren) - Pipeline by Sanofi, 2021
Sicca Syndrome (Sjogren) - Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2021
Sicca Syndrome (Sjogren) - Pipeline by Simcere Pharmaceutical Group Ltd, 2021
Sicca Syndrome (Sjogren) - Pipeline by SinoMab Bioscience Ltd, 2021
Sicca Syndrome (Sjogren) - Pipeline by Spectrix Therapeutics LLC, 2021
Sicca Syndrome (Sjogren) - Pipeline by Surrozen Inc, 2021
Sicca Syndrome (Sjogren) - Dormant Projects, 2021
Sicca Syndrome (Sjogren) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Sicca Syndrome (Sjogren), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021